On Friday, February 5, BMS announced (press release) that the FDA approved Breyanzi (lisocabtagene maraleucel) for the treatment of r/r LBCL after ≥2L systemic therapy, which is essentially ≥3L r/r DLBCL. The application was based on data from the Ph1 TRANSCEND NHL 001 trial. Below, Celltelligence provides insights on Breyanzi’s approval, the higher DLBCL list price vs. Kymriah and Yescarta, how BMS may position Breyanzi in the CD19 CAR-T setting, why supplying Breyanzi in vials is strategically important, and a look at the Breyanzi mobile app.
About The Author
The Celltelligence Team
Content Leads & Contributors
The Celltelligence team has combined experience in oncology, including cell therapy, CAR-T, immunology, microbiology, biochemistry, and other various fields in life sciences. Our team members include PhDs, industry veterans, and analysts tuned to The Street – all of whom help to create a more actionable service of delivering cell therapy intelligence.
If you receive our email blasts, you already have an account. Log in now
Sign UpFREE
You’ll be able to access the full article from your Celltelligence Library after signing up.
If you receive our email blasts, you already have an account. Log in now
Context counts when making decisions.
Sign UpFREE
You’ll be able to access the full article from your Celltelligence Library after signing up.